ArticlePediatric gastroenterology, hepatology & nutrition2026
Use of Noninvasive Biomarker Tests vs. FibroScan for Predicting Significant Fibrosis in Egyptian Pediatric Cancer Survivors with Chronic Hepatitis C Virus Infection.
Article in Pediatric gastroenterology, hepatology & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Egyptian children undergoing chemotherapy are at high risk of hepatitis C virus (HCV) infection because of immunosuppression and multiple blood transfusions. This study evaluated liver fibrosis by comparing transient elastography with aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) in pediatric cancer survivors with chronic HCV infection. Fifty-one cancer survivors with chronic HCV infection (median age, 13.5 years) were prospectively recruited from the pediatric oncology and hepatology clinics at Ain Shams University and the National Cancer Institute. All participants underwent noninvasive fibrosis assessment using transient elastography, APRI, and FIB-4, as well as liver function testing, ultrasonography, and liver biopsy when necessary. Based on liver stiffness measurements, patients were classified into group 1 (fibrosis stage F0-F2; 80.4%) or group 2 (fibrosis stage F3-F4; 19.6%). Compared with group 1, group 2 had significantly higher serum bilirubin and alanine aminotransferase (ALT) levels, lower platelet counts, and higher APRI and FIB-4 scores (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.